Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Lower GI Series market size was valued at approximately USD 1.2 billion in 2024. The market is projected to grow from USD 1.26 billion in 2025 to reach USD 1.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.5% during the forecast period. This growth, while steady, is less explosive than in other diagnostic segments, reflecting the increasing adoption of alternative imaging modalities.
A lower GI series, also known as a barium enema, is a diagnostic radiology procedure used to examine the large intestine (colon and rectum). The procedure involves using x-rays and a radiopaque contrast agent, barium sulfate, to provide visualization of the bowel's inner lining. The two primary techniques are a single-contrast study, which uses only barium to outline the intestine, and a double-contrast study, which uses barium and air to provide a more detailed view of the mucosal surface, enhancing the detection of polyps and inflammations.
The market is primarily sustained by the persistent global burden of colorectal diseases, including cancer, inflammatory bowel disease (IBD), and diverticulitis. However, market growth is tempered by the rising preference for minimally invasive procedures like colonoscopy, which allows for both direct visualization and therapeutic intervention. Nevertheless, the lower GI series remains a valuable, cost-effective tool, particularly for patients for whom colonoscopy is not suitable. Key players such as Guerbet and Bracco Imaging, among others, continue to supply the essential contrast media, supporting the procedure's ongoing use in clinical settings worldwide.
Aging Global Population and Rising GI Disorder Prevalence
The global increase in the elderly population is a primary driver for the Lower GI Series market, as this demographic exhibits a higher susceptibility to colorectal diseases such as cancer, diverticulitis, and inflammatory bowel disease. Concurrently, there is a documented rise in the overall prevalence of gastrointestinal disorders globally, which necessitates diagnostic procedures like the Lower GI Series (barium enema) for effective evaluation and management.
Advancements in Imaging Technologies
Technological improvements in fluoroscopy and digital radiography systems have enhanced the image quality, accuracy, and patient comfort associated with Lower GI Series procedures. The integration of low-dose imaging protocols and enhanced software for image analysis helps in obtaining clearer diagnostic information while minimizing radiation exposure, making the procedure a more attractive option in certain clinical scenarios.
➤ The procedure remains a cost-effective alternative to colonoscopy for structural evaluation of the large intestine in many healthcare settings.
Furthermore, in resource-limited settings or for patients who are not suitable candidates for colonoscopy, the Lower GI Series provides a vital diagnostic tool. Its role in pre-surgical planning and post-operative assessment also contributes to steady procedural volumes.
MARKET CHALLENGES
Competition from Advanced Endoscopic Techniques
A significant challenge for the Lower GI Series market is the strong preference for and increasing adoption of colonoscopy. Colonoscopy offers the distinct advantage of direct visualization, tissue sampling (biopsy), and therapeutic intervention (e.g., polyp removal) during the same procedure, which a purely radiographic study like a Lower GI Series cannot provide.
Other Challenges
Patient Preparation and Discomfort
The rigorous bowel preparation required for a Lower GI Series, which involves dietary restrictions and laxatives, is often cited as a deterrent for patients. The procedure itself can also cause abdominal cramping and discomfort, potentially affecting patient compliance and preference for alternative diagnostics.
Limited Diagnostic Capability for Small Lesions
While effective for identifying larger structural abnormalities, the Lower GI Series has limitations in detecting flat lesions or early-stage, small polyps compared to colonoscopy. This reduced sensitivity for precancerous growths can be a clinical drawback.
Stringent Regulatory Guidelines and Reimbursement Policies
Healthcare reimbursement policies in many regions increasingly favor colonoscopy for colorectal cancer screening, often providing full or higher coverage compared to a Lower GI Series. Stringent regulatory standards for radiation safety and contrast agents also add complexity and cost to providing the service, potentially limiting its adoption in some facilities.
Shift Towards Non-Invasive Screening Tests
The growing popularity of non-invasive stool-based screening tests, such as fecal immunochemical tests (FIT) and multi-target stool DNA tests (e.g., Cologuard), presents a major restraint. These tests offer convenience and avoid bowel preparation and procedural discomfort, capturing a portion of the screening population that might have otherwise undergone a radiographic exam.
Niche Applications in Specific Patient Populations
There is a clear opportunity for the Lower GI Series in diagnosing complex cases where colonoscopy is incomplete, contraindicated, or not feasible. This includes patients with obstructive tumors, severe diverticulitis, or anatomical anomalies that prevent the safe passage of a colonoscope. It serves as an essential problem-solving tool in these specific clinical situations.
Growth in Emerging Markets
Emerging economies present significant growth potential due to improving healthcare infrastructure, rising health awareness, and lower procedural costs compared to colonoscopy. In regions with limited access to specialized endoscopists or advanced endoscopic equipment, the Lower GI Series remains a foundational and widely available diagnostic modality for evaluating the colon.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Double-Contrast procedures are widely recognized as the leading segment due to their superior diagnostic capabilities. The use of both barium and air provides enhanced visualization of the colonic mucosa, allowing for the detection of smaller polyps and subtle mucosal abnormalities that might be missed with single-contrast techniques. This method is particularly valued in screening for colorectal cancer and investigating chronic inflammatory conditions, making it the preferred choice in advanced diagnostic settings despite being a more complex procedure. |
| By Application |
|
Hospitals represent the dominant application segment for Lower GI Series procedures. Their leadership is driven by the availability of comprehensive radiology departments, specialized medical staff, and the capability to handle complex diagnostic cases and subsequent treatments. Hospitals are typically the primary point of care for patients presenting with acute symptoms like gastrointestinal bleeding or severe abdominal pain, which are key indications for a Lower GI Series. The infrastructure to manage patient preparation and potential complications further solidifies the hospital segment's leading position. |
| By End User |
|
Radiology Departments within hospitals and large medical facilities are the foremost end users. Their dominance is attributed to their specialized expertise in interpreting radiographic images and operating the necessary fluoroscopy equipment. These departments are integral to the diagnostic pathway for a wide range of gastrointestinal disorders. The procedural nature of a Lower GI Series, which requires precise technique and expert analysis, aligns perfectly with the core competencies of dedicated radiology departments, ensuring high diagnostic accuracy and patient throughput. |
| By Diagnostic Purpose |
|
Cancer Screening, particularly for colorectal cancer, is a leading driver for Lower GI Series procedures. While colonoscopy is often the gold standard, the Lower GI Series remains a vital non-invasive alternative for patients who cannot undergo endoscopic procedures due to various contraindications. It is instrumental in detecting polyps, tumors, and other precancerous lesions. The persistent global focus on early cancer detection and the procedure's ability to evaluate the entire colon contribute significantly to its sustained use for this critical diagnostic purpose. |
| By Patient Demographics |
|
Geriatric Population constitutes a significant and leading patient demographic for this market. Aging is a major risk factor for many gastrointestinal diseases, including diverticulosis, colorectal cancer, and ischemic colitis. This patient group often presents with symptoms like altered bowel habits and abdominal pain that warrant a Lower GI Series. Furthermore, older patients may have comorbidities that make them unsuitable candidates for more invasive procedures like colonoscopy, thereby increasing the reliance on radiographic studies like the Lower GI Series for safe and effective diagnosis. |
A Dynamic Arena with Established Giants and Specialized Niche Contenders
The competitive landscape of the Lower GI Series market features a mix of large, diversified pharmaceutical and medical device corporations alongside specialized diagnostic imaging companies. Key players like Eisai and AstraZeneca leverage their extensive global reach and R&D capabilities to maintain significant market shares, particularly in the contrast agent segment of the market. The market structure is moderately concentrated, with the top five companies accounting for a notable percentage of the global revenue. These leading entities compete on factors such as product efficacy, safety profiles, strategic partnerships with healthcare providers, and geographic expansion, especially in high-growth regions like Asia.
Beyond the major players, the market includes several other significant companies that hold important positions through niche expertise or regional strength. Firms such as Cadila Pharmaceuticals and Purdue Pharma contribute to the competitive dynamics. Furthermore, specialized players like Novadaq (now part of Stryker) bring technological innovation, particularly in imaging enhancement. The competitive environment is also shaped by regional leaders and hospital-affiliated providers like Peacehealth, which influence market penetration and adoption rates in specific geographic areas. This diverse competitive setup ensures continuous innovation and development in both double-contrast and single-contrast Lower GI series procedures.
List of Key Lower GI Series Companies ProfiledEisai
Purdue Pharma
Peacehealth
Novadaq (Stryker)
Ironwood Pharmaceuticals
GE Healthcare
Siemens Healthineers
Bracco Imaging
Guerbet
FUJIFILM Holdings Corporation
Canon Medical Systems Corporation
The Lower GI Series market is experiencing a significant trend characterized by a gradual shift in procedure preference. While the global market continues to grow, projected to reach US$ million by 2032, there is a notable movement away from traditional barium enema studies. This is primarily driven by the increasing adoption of more advanced and less invasive diagnostic tools such as colonoscopy and CT colonography. These alternatives often provide higher diagnostic accuracy and the ability to perform therapeutic interventions simultaneously. Consequently, the application of Lower GI Series is becoming more specialized, often reserved for patients for whom colonoscopy is contraindicated or incomplete.
Other TrendsDominance of the Double-Contrast Segment
Within the market, the double-contrast Lower GI Series segment holds a dominant position. This technique, which uses both barium and air to coat the colon lining, offers a significantly clearer view of the intestinal mucosa compared to the single-contrast method. The superior diagnostic yield for detecting polyps, diverticula, and inflammatory changes makes it the preferred choice in clinical settings where the procedure is still indicated, contributing to its larger market share.
Consolidation of Hospital-Based Applications
The hospital segment remains the primary application setting for Lower GI Series procedures. Hospitals possess the necessary radiology infrastructure, specialized technologists, and on-site gastroenterology support required for conducting and interpreting these studies. This trend is reinforced by the handling of more complex cases in hospital environments, where patients may have comorbidities that necessitate the procedure over more invasive options.
Regional Market Dynamics and Growth PotentialGeographically, the market dynamics are uneven. Mature markets in North America and Europe are witnessing stabilization or slight decline in procedure volumes due to the widespread adoption of alternative diagnostics. In contrast, the Asia-Pacific region presents a significant growth potential. Factors such as rising healthcare expenditure, improving access to diagnostic imaging in emerging economies, and a growing patient population with gastrointestinal disorders are driving demand in these regions, offsetting slower growth elsewhere and shaping the global market's trajectory towards 2032.
Regional Analysis: Lower GI Series MarketEurope
Europe represents a significant and mature market for Lower GI Series, characterized by variations in adoption and reimbursement across its national healthcare systems. Countries with well-funded public health services, such as Germany, the United Kingdom, and France, demonstrate higher procedure volumes due to systematic screening programs and accessible diagnostic services. The market dynamics are heavily influenced by national health technology assessment bodies that determine the cost-effectiveness and recommended use of diagnostic procedures. In many European nations, there is a strong preference for colonoscopy as the first-line diagnostic tool for colorectal conditions, which can restrain the growth of the Lower GI Series market. However, it maintains a crucial role as a secondary option, particularly for elderly patients or those with contraindications for more invasive procedures. Regulatory harmonization within the European Union facilitates the approval and distribution of contrast media and imaging equipment, though local clinical practices and physician preferences remain key determinants of utilization rates.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for Lower GI Series, driven by expanding healthcare infrastructure, rising healthcare expenditure, and increasing awareness of gastrointestinal diseases. Rapid economic development in countries like China and India is leading to significant investments in hospital imaging capabilities, including fluoroscopy units. The growing middle class with greater access to healthcare services is a primary growth driver. However, market penetration is uneven, with metropolitan areas having advanced facilities while rural regions lag. The diagnostic landscape is also evolving, with a gradual shift from basic X-ray systems to more sophisticated digital radiography. Cultural factors and varying levels of patient awareness about colorectal cancer screening also influence demand. In many parts of Asia-Pacific, the procedure is gaining traction as a cost-effective diagnostic tool compared to colonoscopy, particularly in public healthcare settings aiming to manage large patient populations efficiently.
South America
The South American market for Lower GI Series is developing, with growth potential tied to economic stability and healthcare modernization efforts. Brazil and Argentina are the most prominent markets, featuring larger healthcare systems with both public and private sectors. The public systems often utilize Lower GI Series as a fundamental diagnostic tool due to its relative affordability compared to endoscopic procedures. Challenges include infrastructural limitations outside major urban centers and fluctuating government healthcare spending. Economic volatility can impact the procurement of new imaging equipment and supplies. Nevertheless, there is a growing recognition of the importance of early diagnosis for colorectal cancer, which is gradually increasing the procedure's demand. The market is characterized by a reliance on imports for advanced imaging systems and contrast media, making it sensitive to currency exchange rates and trade policies.
Middle East & Africa
The Middle East & Africa region presents a highly heterogeneous market for Lower GI Series. The affluent Gulf Cooperation Council (GCC) countries, such as Saudi Arabia and the UAE, have modern, well-equipped healthcare systems where the procedure is routinely available in both public and private hospitals. These markets are driven by high per capita health spending and government initiatives to improve non-communicable disease diagnostics. In contrast, many African nations face significant challenges, including a scarcity of specialized radiology equipment and trained personnel, which severely limits access to such diagnostic tests. The market is largely concentrated in urban tertiary care centers. International aid and development programs sometimes play a role in supplying equipment to underserved areas. Overall, the region's growth is bifurcated, with steady adoption in wealthier Middle Eastern countries and very slow, infrastructural-dependent growth in much of Africa.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By Type (Double-Contrast, Single-Contrast)
By Application (Hospital, Clinic, Other)
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Healthcare providers and hospital systems
Medical device and diagnostics manufacturers
Pharmaceutical companies
Investors, consultants, and policy makers
-> Global lower GI series market was valued at USD 1.2 billion in 2024 and is expected to reach USD 1.8 billion by 2032.
-> Key players include Eisai, Cadila Pharmaceuticals, Purdue Pharma, and Astrazeneca, among others.
-> The market is projected to grow at a 4.5% CAGR during the forecast period.
-> The two primary techniques are single-contrast study and double-contrast study.
-> North America currently dominates the global lower GI series market.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates